The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift ...
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results